IGF1 and hepatocellular carcinoma: As for other pathways, small molecules (such as OSI-906) and monoclonal antibodies (such as IMC-A12 and AVE-1642) targeting IGF signaling are under evaluation in clinical trials in HCC patients (Figure 1 and Table 1).